Tät.nu

App study Tät®

We have developed the app Tät® for the treatment of urinary leakage associated with coughing, physical exertion (particularly jumping) and sneezing.

The app is available in Swedish, English, Finnish, German and Spanish for iPhone and Android phones. It contains exercises programmes with graded levels of difficulty, a statistical function and an option to create various reminders.

We have examined the efficacy of treatment via the app in a study in which 123 women were assigned to treatment via the app or to a control group which did not have access to the app until after the first follow-up. We compared the results with regard to symptoms, quality of life and leakage before and after treatment. We also compared the results from the control group and the app group after three months of treatment. Nine out of ten women in the app group showed improvement, compared with two out of ten women in the control group. Women in the app group showed improvements with regard to degree of severity and quality of life and also experienced a decrease in the frequency of urinary leakage from an average of three times a day to once a day. The improvement in these variables was statistically significant in the app group, but not in the control group. The results were presented as an abstract at a scientific conference where it was awarded a prize for the best abstract in the category ”conservative treatment”. The complete results were published in September 2016 in the journal Neurourology and Urodynamics, see link. A health economic analysis concluded that the app was a new, cost-effective, first-line treatment option, see link. We have also conducted a long term follow-up (two years), see link and an interview-based study, see linc.

The study is registered with Clinical Trials www.clinicaltrials.gov (ID NCT01848938)

11 Jun 2024

The Tät-m app has been launched in collaboration with the Swedish Prostate Cancer Federation

The name of the app has been changed from TätIII to Tät-m and it has a new logo, a new design and simpler navigation. The app is now provided via eContinence AB in collaboration with the the Swedish Prostate Cancer Federation.

Thanks to all men who have responded to the questionnaires over the years. Your contribution has helped to increase knowledge about pelvic floor muscle training and urinary leakage.

11 Mar 2024

Clinically relevant improvement depends on baseline severity

In a recently published study, we analysed how large reduction on the symptom score ICIQ –UI SF was required for a clinically relevant improvement. The results showed that it depended on the baseline severity, more symptoms required larger reductions to perceive improvement. Full-text article available here

27 Jan 2024

Treatment results at 15 weeks are important for long-term satisfaction

At the long-term follow-up after 15 months, 58% of the women were satisfied with treatment of mixed and urgency urinary incontinence with the app Tät®II. In further analyses, important factors for long-term satisfaction were quality of life at baseline, along with ability to endure urgency, and confidence in pelvic floor contraction at short-term-follow up. Full-text article available here The Tät®II app is currently not available, but a new study is planned.

20 Jun 2023

The Tät® III app in a new updated version

We have previously demonstrated that this app facilitates training for men undergoing radical prostatectomy. More than 10 000 men have used the app. Now, we want to study if the app affects the need for contacts with health care facilities. The app is updated with new content, new illustrations and questionnaires. The app is free to download at App Store and Google Play.

30 Aug 2022

A brand new version of the Tät® app is now available from App Store

The pink app, which is now being produced by eContinence AB, contains simpler free content and the possibility to upgrade to Premium with new exciting content and new features. Initially the app will not be available in all countries due to the CE marking regulations there. Find out more here

Read more news